{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:20:30Z","timestamp":1792182030280,"version":"4.4.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,10,15]],"date-time":"2020-10-15T00:00:00Z","timestamp":1602720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) are increasingly used in various solid organ malignancies. However, there are limited data regarding their safety and efficacy in solid organ transplant (SOT) recipients. The aim of this study was to review our experience with ICIs in SOT recipients with advanced head and neck cutaneous squamous cell carcinoma (cSCC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A retrospective review of ICIs used in SOT recipients from April 2011 to September 2019 was undertaken. Patient clinical and demographic features, ICI regimen, immunosuppression, treatment efficacy, and adverse events were reviewed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The seven SOT recipients (four kidney, two liver, one lung) were diagnosed with metastatic head and neck cSCC. All had undergone prior locoregional surgery and adjuvant radiation therapy. At a median of 10.8\u2009years (range, 6.6\u201318.1) post-transplant, six were treated with cemiplimab and one with pembrolizumab after minimizing calcineurin inhibitors (CNIs) or conversion of CNI to mammalian target of rapamycin (mTOR) inhibitors. During a median follow-up of 7.1 months, overall tumor response rate was 57.1% with one complete responder and three partial responders. Four patients died at a median of 135\u2009days after starting ICI with two dying from tumor progression and two dying from other causes. Regarding adverse events, one lung transplant recipient developed severe pneumonitis that resolved with high-dose steroids, and one renal transplant patient developed progressive renal injury and died of unrelated causes. The three patients who received prophylactic prednisone all responded to cemiplimab with preserved allograft function and no adverse events.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our data suggest that minimization of CNI and conversion of CNI to mTOR inhibitors along with judicious use of prophylactic steroids may allow for the safe use of ICIs in SOT recipients with advanced cSCC. Short-term efficacy appears promising, but prospective studies with further follow-up and a standardized protocol for prophylactic steroids are needed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Implications for Practice<\/jats:title>\n                  <jats:p>Solid organ transplant (SOT) recipients are at increased risk of developing malignancy because of long-term post-transplant immunosuppression. Although immune checkpoint inhibitors (ICIs) are increasingly shown to be successful in treating multiple types of cancer, SOT recipients have been excluded from clinical trials because of concerns regarding potential allograft rejection. This pilot study provides evidence that ICIs along with prophylactic steroids may be a safe and efficacious treatment option for selected SOT recipients with advanced cutaneous squamous cell carcinoma. However, further prospective studies using ICIs in this high-risk patient population are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/onco.13539","type":"journal-article","created":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T04:52:36Z","timestamp":1600923156000},"page":"133-138","source":"Crossref","is-referenced-by-count":74,"title":["A Pilot Study of Checkpoint Inhibitors in Solid Organ Transplant Recipients with Metastatic Cutaneous Squamous Cell Carcinoma"],"prefix":"10.1093","volume":"26","author":[{"given":"Irene","family":"Tsung","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis P.","family":"Worden","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fontana","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,10,15]]},"reference":[{"key":"2021122511545981500_onco13539-bib-0001","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2021122511545981500_onco13539-bib-0002","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: The Mayo Clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"2021122511545981500_onco13539-bib-0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1634\/theoncologist.2019-0659","article-title":"The safety and efficacy of checkpoint inhibitors in transplant recipients: A case series and systematic review of literature","volume":"25","author":"Kumar","year":"2020","journal-title":"The Oncologist"},{"key":"2021122511545981500_onco13539-bib-0004","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jaad.2010.11.062","article-title":"Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part I. Epidemiology of skin cancer in solid organ transplant recipients","volume":"65","author":"O'Reilly Zwald","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2021122511545981500_onco13539-bib-0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0140-6736(09)61196-X","article-title":"Non-melanoma skin cancer","volume":"375","author":"Madan","year":"2010","journal-title":"Lancet"},{"key":"2021122511545981500_onco13539-bib-0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jaad.2010.11.063","article-title":"Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part II. Management of skin cancer in solid organ transplant recipients","volume":"65","author":"O'Reilly Zwald","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2021122511545981500_onco13539-bib-0007","doi-asserted-by":"crossref","first-page":"104459","DOI":"10.1016\/j.oraloncology.2019.104459","article-title":"Immunotherapy and other systemic therapies for cutaneous SCC","volume":"99","author":"Guminski","year":"2019","journal-title":"Oral Oncol"},{"key":"2021122511545981500_onco13539-bib-0008","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122511545981500_onco13539-bib-0009","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: A comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021122511545981500_onco13539-bib-0010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting autoimmune disease: Implications for immune checkpoint inhibitor therapy in solid tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122511545981500_onco13539-bib-0011","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"suppl 15","key":"2021122511545981500_onco13539-bib-0012","doi-asserted-by":"crossref","first-page":"9547a","DOI":"10.1200\/JCO.2019.37.15_suppl.9547","article-title":"Pembrolizumab as first-line therapy in patients with unresectable cutaneous squamous cell carcinoma (cSCC): Phase II results from CARSKIN","volume":"37","author":"Maubec","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"2021122511545981500_onco13539-bib-0013","doi-asserted-by":"crossref","first-page":"TPS9598a","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS9598","article-title":"KEYNOTE-629: Phase 2 study of pembrolizumab for recurrent\/metastatic or locally advanced unresectable cutaneous squamous cell carcinoma (cSCC)","volume":"37","author":"Grob","year":"2019","journal-title":"J Clin Oncol"},{"key":"2021122511545981500_onco13539-bib-0014","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1600-0625.2011.01413.x","article-title":"Skin cancer in organ transplant recipients: Effects of immunosuppressive medications on DNA repair","volume":"21","author":"Kuschal","year":"2011","journal-title":"Exp Dermatol"},{"key":"2021122511545981500_onco13539-bib-0015","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab","volume":"376","author":"Barnett","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122511545981500_onco13539-bib-0016","volume-title":"Tarrytown, NY and Bridgewater, NJ: Regeneron Pharmacceuticals\/Sanofi-Aventis U.S","author":"Libtayo (cemiplimab) [package insert]","year":"2018"},{"key":"2021122511545981500_onco13539-bib-0017","volume-title":"Whitehouse Station, NJ: Merck and Company","author":"Keytruda (pembrolizumab) [package insert]","year":"2020"},{"key":"2021122511545981500_onco13539-bib-0018","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/TP.0000000000002482","article-title":"Donor-specific cell-free DNA as a biomarker in solid organ transplantation: A systematic review","volume":"103","author":"Knight","year":"2019","journal-title":"Transplantation"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/onco.13539","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/onco.13539","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/2\/133\/41923369\/oncolo_26_2_133.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/26\/2\/133\/41923369\/oncolo_26_2_133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:57:56Z","timestamp":1640433476000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/26\/2\/133\/6445354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,15]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,10,15]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1002\/onco.13539","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,10,15]]}}}